Trials / Completed
CompletedNCT03056690
A Study to Assess the Analgesic Efficacy and Safety of ASP0819 in Patients With Fibromyalgia
A Phase 2a, Randomized, Double-Blind Placebo-controlled, Parallel-group Study to Assess the Analgesic Efficacy and Safety of ASP0819 in Patients With Fibromyalgia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 186 (actual)
- Sponsor
- Astellas Pharma Global Development, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This study assessed analgesic efficacy of ASP0819 relative to placebo as well as the safety and tolerability. This study assessed treatment differences in physical function as well as the improvements in overall subject status (e.g., fibromyalgia symptoms and global functioning) of ASP0819 relative to placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ASP0819 | Oral capsule |
| DRUG | Placebo | Oral capsule |
Timeline
- Start date
- 2017-03-20
- Primary completion
- 2018-02-27
- Completion
- 2018-02-27
- First posted
- 2017-02-17
- Last updated
- 2024-10-29
- Results posted
- 2021-03-03
Locations
24 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03056690. Inclusion in this directory is not an endorsement.